source
- FDA opens investigation into Novartis' Zolgensma after cancer cases reportedThe U.S. Food and Drug Administration announced on Friday that it is opening a formal investigation into the gene-therapy product Zolgensma, marketed by Novartis for spinal muscular atrophy. The a…
- Novo and Novartis see heart drug setbacks as trials show minimal efficacyNovo's cardiovascular candidate failed to demonstrate meaningful benefit in its pivotal study, causing the company's shares to fall about 9% in July. The trial data showed the drug had little effe…